Several factors are associated with increased mortality in patients with bullous pemphigoid, with mortality rates increasing 5 years after diagnosis.

Recent studies highlight the potential pathophysiology and presentation of immune checkpoint inhibitor–associated cutaneous ...

Bullous pemphigoid (BP) is a well-known condition triggered by autoantibodies directed against hemidesmosomal proteins involved in the adhesion of basal keratinocytes to the basement membrane.

Dupilumab use among adults with bullous pemphigoid was associated with significant improvements in several efficacy measures, with no new safety signals identified. Dupilumab offers significant ...

Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based ...